Loading
Maze Therapeutics, Inc. Stock: price and insider trades · United States
US·Mcap US$1.5B
Maze Therapeutics, Inc.: what insiders have been doing
Maze Therapeutics, Inc. is a listed company. Its directors and officers file their transactions with SEC (Form 4). Between 18 October 2025 and 18 October 2026, 11 insiders published 93 filings.
The flow runs one way only: 51 sales worth €7.1M, from 5 insiders, and no purchase. The amount is not disclosed for 6 filings. One trade stands out by size: a sale of €761k from Coloma Jason V, disclosed on 2 October 2026, or 0.057% of market capitalisation.
Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Compared with its exchange (5,458 companies, median 22 filings), a count of 93 filings is above the norm. Our records for Maze Therapeutics, Inc. go back to 2025, with no purchases and 52 sales on the open market in total.
In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
97
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€8M
52 ops. · all time
Who traded when
BuySaleJason Coloma V18 sales
Harold Bernstein15 sales
Atul Dandekar12 sales
Phillips Courtney4 sales
Bachrodt Amy2 sales
Scheller Richard H1 sale
Analyst consensus: bullish or bearish?
Analysts rate Maze Therapeutics, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$61.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 23,547 of 24,148 companies
11.3
score / 100
Value18
Quality5
FCF yld-7.4%
Earn yld-8.6%
EV/EBITDA·
ROE-37%
Gross mgn·
Net mgn-91%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$27.48
Analyst consensus
12 analystsStrong buy
US$46.00Target US$61.50(+124%)US$110.00
Income statement
RevenueUS$144.2M
EBITDA-US$140.5M-97% margin
Net income-US$131.1M0.0% margin
Valuation
PER (forward)-8.5x
P/Book3.4x
Balance sheet & cash
Market capUS$1.5B
Total debtUS$23.3M
Free Cash Flow-US$112.7M
Debt / Equity13%
Profitability & ownership
ROE-37.3%
ROA-21.8%
% insiders1.5%
% institutions106.9%
Last declaration on 2 October 2026
Declarations97 total
31,908 shares@ US$27.0210.057% mcap12.3% of flowCommon StockSEC:0001676170-26-000024:1
16,141 shares@ US$26.93410.029% mcap9.1% of flowCommon StockSEC:0002050172-26-000038:1
2,593 shares@ US$27.02410.0046% mcap1.0% of flowCommon StockSEC:0001676170-26-000024:0
16,141 shares@ US$10.420.011% mcap3.5% of flowCommon StockSEC:0002050172-26-000038:0
16,141 shares@ US$27.18100.0% of flowCommonSEC144:0001950047-26-009933
34,501 shares@ US$27.050.062% mcap15.4% of flowCommonSEC144:0001969223-26-001044
7,500 shares@ US$10.420.0052% mcap3.2% of flowCommon StockSEC:0002050167-26-000030:0
7,500 shares@ US$27.05610.013% mcap8.3% of flowCommon StockSEC:0002050167-26-000030:1
9,705 shares@ US$26.22380.017% mcap6.0% of flowCommon StockSEC:0002050172-26-000036:0
9,705 shares@ US$25.870.017% mcap14.9% of flowCommonSEC144:0001950047-26-009147
9,852 shares@ US$26.3760.018% mcap5.0% of flowCommon StockSEC:0001676170-26-000022:0
1,375 shares@ US$27.12110.0025% mcap0.7% of flowCommon StockSEC:0001676170-26-000022:1
11,282 shares@ US$26.01330.020% mcap5.6% of flowCommon StockSEC:0001676170-26-000022:2
129 shares@ US$25.77490.0002% mcap0.1% of flowCommon StockSEC:0001676170-26-000022:3
1,738 shares@ US$26.3760.0031% mcap43.8% of flowCommon StockSEC:0001782758-26-000008:0
243 shares@ US$27.12110.0004% mcap6.3% of flowCommon StockSEC:0001782758-26-000008:1
1,990 shares@ US$26.01330.0035% mcap49.4% of flowCommon StockSEC:0001782758-26-000008:2
22 shares@ US$25.780.0000% mcap0.5% of flowCommon StockSEC:0001782758-26-000008:3
2,800 shares@ US$26.3760.0050% mcap3.4% of flowCommon StockSEC:0002050167-26-000027:0
391 shares@ US$27.12110.0007% mcap0.5% of flowCommon StockSEC:0002050167-26-000027:1
3,207 shares@ US$26.01330.0056% mcap3.8% of flowCommon StockSEC:0002050167-26-000027:2
36 shares@ US$25.810.0001% mcap0.0% of flowCommon StockSEC:0002050167-26-000027:3
4,481 shares@ US$26.3760.0080% mcap2.8% of flowCommon StockSEC:0002050172-26-000034:0
625 shares@ US$27.12110.0011% mcap0.4% of flowCommon StockSEC:0002050172-26-000034:1
5,130 shares@ US$26.01330.0090% mcap3.1% of flowCommon StockSEC:0002050172-26-000034:2
25 of 97 declarations
About Maze Therapeutics, Inc.
Maze Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for genetic diseases. It employs innovative approaches to identify and develop targeted treatments.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
